Simulations Plus (NASDAQ:SLP) is set to announce its earnings results after the market closes on Wednesday, November 13th. Analysts expect the company to announce earnings of $0.09 per share for the quarter.
Simulations Plus stock traded up $0.33 during mid-day trading on Thursday, hitting $33.31. 1 shares of the company’s stock were exchanged, compared to its average volume of 94,460. The stock has a market cap of $607.29 million, a P/E ratio of 65.96 and a beta of -0.34. Simulations Plus has a 1-year low of $17.18 and a 1-year high of $41.95. The stock has a 50 day moving average of $34.61 and a two-hundred day moving average of $31.38.
The firm also recently announced a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Friday, October 25th were given a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a yield of 0.72%. The ex-dividend date was Thursday, October 24th. Simulations Plus’s payout ratio is 48.00%.
Several brokerages have recently issued reports on SLP. Zacks Investment Research raised Simulations Plus from a “hold” rating to a “buy” rating and set a $38.00 price target on the stock in a research report on Wednesday, October 30th. ValuEngine cut shares of Simulations Plus from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. BidaskClub cut shares of Simulations Plus from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Liberum Capital restated a “buy” rating on shares of Simulations Plus in a research note on Tuesday, October 22nd. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Simulations Plus has an average rating of “Hold” and an average target price of $38.00.
In related news, Director Walter S. Woltosz sold 24,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 24th. The shares were sold at an average price of $35.86, for a total transaction of $860,640.00. Following the completion of the transaction, the director now owns 5,087,918 shares of the company’s stock, valued at $182,452,739.48. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders sold 72,000 shares of company stock valued at $2,532,720 over the last 90 days. Corporate insiders own 31.57% of the company’s stock.
About Simulations Plus
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Featured Story: Conference Calls and Individual Investors
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.